Skip to main content

Advertisement

Table 1 Patient/tumor characteristics and the use of androgen deprivation therapy (ADT) between patients without (n = 401) and with (n = 18) lymph node (LN) recurrence

From: The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer

Variable Without LN With LN
Number (%) Number (%)
Age  
 <70 134 (33.4) 5 (27.7)
 ≥70 267 (66.6) 13 (72.3)
T stage  
 1a 5 (1.2) 0 (0)
 1b 6 (1.5) 0 (0)
 1c 124 (30.9) 3 (16.7)
 2a 52 (13.0) 1 (5.6)
 2b 40 (10.0) 3 (16.7)
 2c 42 (10.5) 0 (0)
 3a 72 (18.0) 2 (11.1)
 3b 53 (13.2) 7 (38.9)
 4 7 (1.7) 2 (11.1)
Gleason score  
 <7 125 (31.2) 3 (16.7)
 7 185 (46.1) 4 (22.2)
 8–10 91 (22.7) 11 (61.1)
PSA (ng/ml)  
 <10 117 (29.2) 4 (22.2)
 10–20 119 (29.7) 5 (27.7)
 ≥20 165 (41.1) 9 (50.0)
Risk group  
 Low 41 (10.2) 1 (5.6)
 Intermediate 121 (30.2) 1 (5.6)
 High 180 (44.9) 7 (38.9)
 Very high 59 (14.7) 9 (50.0)
Any ADT
 No 57 (14.2) 2 (11.1)
 Yes 344 (85.8) 16 (88.9)
Neoadjuvant ADT
 No 127 (31.7) 4 (22.2)
 Yes 274 (68.3) 14 (77.8)
Concurrent ADT
 No 103 (25.7) 8 (44.4)
 Yes 298 (74.3) 10 (55.6)
Maintenance ADT
 No 177 (44.1) 9 (50.0)
 Yes 224 (55.9) 9 (50.0)